BioElectronics Announces Health Economics Study
(firmenpresse) - FREDERICK, MD -- (Marketwired) -- 06/29/17 -- BioElectronics Corporation (OTC PINK: BIEL), is pleased to announce the completion of a health economics study using its nonprescription drug-free ActiPatch® Musculoskeletal Pain Therapy for chronic pain. The goal was to investigate how using ActiPatch as a pain therapy would affect overall healthcare costs in the UK.
The study involved thirty subjects and compared overall healthcare costs (drugs, physician visits etc.) between a baseline 3-month period and 3 months of using ActiPatch® therapy. In summary, subjects reported a:
53% reduction in primary care appointments
42% reduction in pain specialist appointments
75% reduction in physiotherapy appointments
37% reduction in prescription analgesic use
In addition to a significant reduction in pain and improvement in quality of life, ActiPatch use was found to result in a 42% net direct savings in healthcare costs.
ActiPatch® Musculoskeletal Pain Therapy is based on the newest understanding of chronic pain: chronic pain often results because nerves "learn" pain, a process known as central sensitization. ActiPatch is a wearable medical device that regulates nerve activity (neuromodulation) 24/7. This results in reduced nerve hyperactivity and provides effective pain relief. The drug-free devices are available on Amazon for $29.95 (720-hours) of on/off therapy or $9.95 for the 7-Day Trial device.
"This study provides strong economic and marketability evidence that when ActiPatch® is used as an active therapy for chronic pain, not only does it reduce chronic pain but it also significantly reduces the overall healthcare costs associated with managing chronic pain," stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit .
Paul Knopick
940.262.3584
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2017 - 09:06 Uhr
Sprache: Deutsch
News-ID 1511706
Anzahl Zeichen: 2519
contact information:
Contact person:
Town:
FREDERICK, MD
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 363 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioElectronics Announces Health Economics Study
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioElectronics Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
